Valeant Reports Third Quarter 2016 Financial Results

Rodman & Renshaw Downgrades Valeant Pharmaceuticals (VRX) to Neutral

Rodman & Renshaw downgraded Valeant Pharmaceuticals (NYSE: VRX) from Buy to Neutral with a price target of $23.00 (from $81.00). The change follows its Q3 revenue and earnings miss.

Analyst Raghuram Selvaraju said, "In its financial results for 3Q16 reported earlier this week, Valeant reported adjusted... More

Moody's Downgrades Valeant Pharma (VRX) CFR to B3 from B2; Outlook Negative

Moody's Investors Service downgraded the ratings of Valeant Pharmaceuticals International, Inc. (NYSE: VRX) and subsidiaries, including the Corporate Family Rating to B3 from B2 and the Probability of Default Rating to B3-PD from B2-PD. Other downgrades include the senior secured bank credit facilities to Ba3 (LGD 2) from Ba2 (LGD 2) and senior unsecured debt to Caa1 (LGD 5) from B3 (LGD 5). At the same time, Moody's affirmed Valeant's SGL-3 Speculative Grade Liquidity Rating. The rating outlook is negative.

The downgrade reflects Valeant's challenges in turning around its specialty pharmaceuticals business, resulting in weak... More

Guggenheim Remains Positive on Valeant (VRX) post Q3: 'In the Kitchen Sink, but Not Down the Drain'

Guggenheim analyst Louise Chen weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the company reported, as expected, a 3Q16 miss and lowered its '16 EPS guidance.

Chen commented, "VRX has noted since its 1Q16 call that the business should start to recover in 2H16. Evidence of this was demonstrated in 3Q16 as VRX reported sequential improvements in sales and EBITDA throughout the year. Therefore, despite the miss and... More

Valeant Pharma (VRX) Sees Solid Bounce Off Morning Lows

Valeant Pharma (NYSE: VRX) has moved solidly off morning lows but remains down 20.5% to $15.21. Shares were down as much as 28% to $13.77 earlier.

The bounce could be short covering.

Biggest Takeaway from Valeant (VRX) Call is 2017 Revs and EBITDA Expected to Be Below 2016 - Evecore ISI's Raffat

Evecore ISI analyst Umer Raffat said by far the biggest takeaway from Valeant Pharma (NYSE: VRX) call is that 2017 revenues and EBITDA is expected to be below 2016. The CFO flagged generic competition against Isuprel, Virazole, Syprine, Mephyton etc.

Raffat said the single... More

Valeant Pharma (VRX) Sinks 27% in Pre-Open Trade, Falling Below $14

Valeant Pharma (NYSE: VRX) is free-fall pre-open. Shares are down 27% to $13.92.

Valeant (VRX) Misses, Lowers, Delays - Wells Fargo's Maris

Wells Fargo analyst David Maris offered some comments on Valeant Pharmaceuticals (NYSE: VRX) following its Q3 miss and lower outlook.

Maris commented, "Valeant reported 3Q results that missed expectations. Revenue of $2.48 billion missed our estimate of $2.74 billion and consensus of $2.51 billion. Valeant's adjusted EPS of $1.55 missed our $1.95 estimate and consensus of $1.75. We had assumed Valeant would experience some tailwinds from pricing, higher rebates, and increased prior-authorizations; however, it appears... More

Valeant (VRX) Miss and Guide Down Expected, But Magnitude Maybe Not - Mizuho

Mizuho Securities analyst Irina Koffler weighed in on Valeant Pharmaceuticals (NYSE: VRX) after the 3Q:16 miss and lowered guide, which were widely expected but perhaps the magnitude was not.

Koffler commented, "Valeant reported $2.48B in revenues and non-GAAP EPS of $1.55 vs. $2.51B and $1.75 StreetAccount... More

Valeant (VRX) Q3 a Mixed Bag, Guidance Cut on Higher Side of Expectations - BMO

BMO Capital analyst Gary Nachman weighed in on Valeant Pharmaceuticals (NYSE: VRX) following mixed Q3 results and 2016 guidance reset.

Nachman commented, "VRX reported 3Q revenue of $2,480mn vs. our/consensus of $2,463/2,511mn. Adj. EPS was $1.55 vs. our/consensus of $1.65/1.75. The quarter was mixed, with a lot of moving parts.... More

Valeant Pharma (VRX) EBITDA Was North of $1B, Which Was Better than Feared - Evecore ISI Raffat

Evecore ISI analyst Umer Raffat weighed in on Valeant Pharma (NYSE: VRX) quarter. He notes that based on his investor conversations, buyside sentiment had MASSIVELY shifted when the stock moved from ~$30 to... More